サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1464691

ウイルスベクターおよびプラスミドDNA製造市場：ベクタータイプ別、ワークフロー別、最終用途別、治療領域別、国別、地域別- 産業分析、市場規模、市場シェア、2024年～2032年予測

Viral Vector and Plasmid DNA Manufacturing Market, By Vector Type, By Workflow, By Application, By End-use, By Therapeutic Area, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

出版日
ページ情報
英文 345 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
ウイルスベクターおよびプラスミドDNA製造市場：ベクタータイプ別、ワークフロー別、最終用途別、治療領域別、国別、地域別- 産業分析、市場規模、市場シェア、2024年～2032年予測
出版日: 2024年04月01日
発行: AnalystView Market Insights
ページ情報: 英文 345 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

レポートハイライト

ウイルスベクターおよびプラスミドDNA製造市場規模は2023年に54億500万米ドルと評価され、2024年から2032年にかけてCAGR 19.7%で拡大

ウイルスベクターおよびプラスミドDNA製造市場-市場力学

細胞ベースの研究に対する政府支援の増加が市場需要を促進

ウイルスベクターおよびプラスミドDNA製造市場は、ウイルスベクターを製造するための新技術や施設の設立に対する政府からの資金援助が増加した結果、全体的な研究活動が活発化し、細胞ベースの研究が支援されるようになり、成長が見込まれています。さらに、市場拡大を促進する主な要因は、がんや心臓の異常を含む疾病の有病率の増加、細胞療法研究の利用、ウイルスベクター＆プラスミドDNA製造分野における技術進歩です。例えば、カナダ政府は国民の健康増進のため、ゲノミクスと再生医療への投資を行った。幹細胞ネットワークの競争的研究資金イニシアティブを通じて、430万米ドルが授与されました。多発性硬化症、筋ジストロフィー、がん、血液疾患、1型糖尿病、心臓病、嚢胞性線維症などの健康問題の治療を目指すカナダ各地の16のイニシアチブが、この直接資金によって支援されます。再生医療に重点を置いた幹細胞研究イニシアチブを立ち上げようとしている、保健、生物工学、社会科学の若手研究者を支援する新しいプログラムは、この競合で取り上げられた資金提供の機会のひとつです。さらに、ゲノム・カナダを通じて、新たに10件のゲノム研究に1,600万米ドルが提供されます。2035年までに、この投資は生物医学と医薬品開発の変革に貢献すると思われます。また、農業、健康、環境の分野における現実の問題や可能性に取り組む、直接的な応用が期待できる使命感あふれる研究も支援されます。

製品上市の増加は市場収益成長の潜在的機会を提供する

製品上市の増加は、予測期間中に市場成長の潜在的機会を提供すると予想されます。例えば、2023年3月には、Charles River Laboratories International, Inc.の既製のpHelperサービスの導入により、アデノ随伴ウイルス（AAV）ベースの遺伝子治療イニシアチブは、初期の発見から商業的製造まで、より効率的に管理できるようになりました。調査グレード（RG）、高品質グレード（HQ）、適正製造基準（GMP）グレードのすべてが即座に利用可能です。

ウイルスベクターおよびプラスミドDNA製造市場-主要インサイト

リサーチアナリストの分析によると、世界市場は予測期間（2024-2032年）に約19.7%のCAGRで年間成長すると予測されています。

ベクタータイプ別では、アデノ随伴ウイルス（AAV）セグメントが予測期間で最大の市場シェアを占めると予測されます。

ワークフロー別では、下流製造が予測期間中に大きな市場シェアを占めると予想されます。

治療分野別では、予測期間中、腫瘍性疾患分野が突出した市場シェアを占めると予測されます。

地域別では、北米が2023年の主要収益源となる

ウイルスベクターおよびプラスミドDNA製造市場-セグメンテーション分析：

世界のウイルスベクターおよびプラスミドDNA製造市場は、ベクタータイプ、ワークフロー、用途、最終用途、治療領域、地域に基づいてセグメント化されます。

ベクタータイプに基づき、ウイルスベクターおよびプラスミドDNA製造市場は、アデノウイルス、レンチウイルス、アデノ随伴ウイルス（AAV）、レトロウイルス、プラスミド、バキュロウイルス、センダイウイルス、その他（単純ヘルペスウイルス（HSV）など）にセグメント化されます。アデノ随伴ウイルス（AAV）セグメントは予測期間中最大の市場シェアを占めると予想されます。AAVは、遺伝子を目的の場所に送達する精度が非常に高いため、非常に人気があり、臨床試験で急速に使用されています。整形外科用および眼科用遺伝子治療薬の開発に関する臨床研究では、有効性と効率の向上が示されており、これが採用増加の理由となっています。

ワークフローに基づき、ウイルスベクターおよびプラスミドDNA製造業界は上流製造と下流製造に二分されます。下流製造セグメントは、治療グレードの最終製品を研磨・精製するために使用される非常に複雑なプロセスのため、予測期間中に大きな市場シェアを占めると予想されます。

用途に基づき、市場はアンチセンス＆RNAi療法、ワクチン療法、遺伝子療法、組織工学、細胞療法、調査用途、その他（バイオセンサーなど）に二分されます。

最終用途に基づくと、業界は製薬・バイオ製薬会社、製造受託機関（CMO）、研究機関、その他（政府機関など）に二分されます。

治療分野に基づくと、ウイルスベクターおよびプラスミドDNA製造市場は、神経疾患、感覚器疾患、筋骨格系疾患、代謝疾患、腫瘍疾患、希少疾患、血液疾患、免疫疾患、その他（生殖医療など）に二分されます。予測期間中、腫瘍性疾患分野が突出した市場シェアを占めると予想されます。このセグメントの成長は、世界中でがんの有病率が上昇していることに起因しています。例えば、国際がん研究機関（IARC）の最新の推計によると、2022年には新たに2,000万人ががんに罹患し、970万人ががんで死亡すると予測されています。がんの診断を受けてから5年後も生存している人は5,350万人と予測されています。5人に1人が人生のどこかでがんに罹患し、男性の9人に1人、女性の12人に1人がこの病気でこの世を去ることになります。このように、前述の統計がこの分野の拡大を後押ししています。

ウイルスベクターおよびプラスミドDNA製造市場-地理的洞察

地理的には、この市場は北米、ラテンアメリカ、欧州、アジア太平洋、中東・アフリカの地域に広がっています。これらの地域は、ビジネスをもたらす国によってさらに分けられます。予測期間中、北米が最大の市場シェアを占めると予想されています。これは、同地域における開発受託機関の増加や、遺伝子・細胞治療研究および製品開発への企業の関与の増加によって説明されます。さらに、地域企業はこの地域で生産工場を増やしています。GMP製造サービスを提供するCDMOのような重要な市場参入企業が存在し、製造には独創性の高い製造方法が用いられていることから、米国はウイルスベクターおよびプラスミドDNA製造の北米市場で最大の収益シェアを占めています。

ウイルスベクターおよびプラスミドDNA製造市場-競合情勢：

いくつかの大手企業は、市場での地位を向上させ、顧客に幅広いサービスを提供するために、戦略的な取り組みを実施しています。市場での存在感と収益を高め、競争力を獲得するために、企業はパートナーシップや契約、ジョイントベンチャー、事業拡大、サービス開始、製品革新、市場成長を促進するその他の戦術に頻繁に取り組んでいます。近年、プラスミドDNAとウイルスベクターの市場では、注目すべきレベルの技術革新が見られます。プラスミドDNAやウイルスベクターの生産者は、遺伝子治療やワクチン開発の強化に対する需要の高まりに対応するため、絶えず新しく効果的なソリューションを模索しています。ウイルスベクターの大規模製造に一過性トランスフェクション技術を使用することは、この市場における主要な発展の一つです。ウイルスベクターの製造に懸濁細胞培養技術を利用することも革新的なアプローチです。大手バイオテクノロジー企業や製薬企業は、特許技術や知識、製造能力を利用するために、中小のベクターやプラスミドDNA製造企業を頻繁に買収しています。その結果、市場の統合が進み、価格設定や市場シェアに対する既存企業の力が強まっています。大企業のインフラやリソースを活用することで、中小企業は事業を拡大し、新たな市場に参入することができます。例えば、2022年2月、エグゼリードはメルクKGaAに約7億8,000万米ドルで買収されました。エンドユーザーにmRNAのバリューチェーンに沿った完全なエンド・ツー・エンドのCDMOサービスを提供することで、メルクのライフサイエンス分野のサービスはさらに向上すると思われます。

目次

第1章 ウイルスベクターおよびプラスミドDNA製造市場概要

  • 調査範囲
  • 市場推定年

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 ウイルスベクターおよびプラスミドDNA製造の主要市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 ウイルスベクターおよびプラスミドDNA製造産業研究

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しマッピング
  • 規制枠組み分析

第5章 ウイルスベクターおよびプラスミドDNA製造市場： COVID-19の影響分析

  • COVID-19以前の影響分析
  • COVID-19後の影響分析

第6章 ウイルスベクターおよびプラスミドDNA製造市場情勢

  • ウイルスベクターおよびプラスミド DNA製造市場シェア分析、2023年
  • 主要メーカー別内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 ウイルスベクターおよびプラスミドDNA製造市場- ベクタータイプ別

  • 概要
    • ベクタータイプ別セグメントシェア分析
    • アデノウイルス
    • レンチウイルス
    • アデノ随伴ウイルス（AAV）
    • レトロウイルス
    • プラスミド
    • バキュロウイルス
    • センダイウイルス
    • その他（単純ヘルペスウイルス（HSV）など）

第8章 ウイルスベクターおよびプラスミドDNA製造市場- ワークフロー別

  • 概要
    • ワークフロー別セグメントシェア分析
    • 上流製造
      • ベクター増幅と拡張
      • ベクターの回収/収穫
    • 下流製造
      • 精製
      • 充填仕上げ

第9章 ウイルスベクターおよびプラスミドDNA製造市場- 用途別

  • 概要
    • 用途別セグメントシェア分析
    • アンチセンスおよびRNAi療法
    • ワクチン学
    • 遺伝子治療
    • ヒト組織工学
    • 細胞療法
    • 調査
    • その他（バイオセンサー等）

第10章 ウイルスベクターおよびプラスミドDNA製造市場- 最終用途別

  • 概要
    • 最終用途別セグメントシェア分析
    • 製薬・バイオ医薬品企業
    • 契約製造組織（CMO）
    • 調査機関
    • その他（政府機関等）

第11章 ウイルスベクターおよびプラスミドDNA製造市場- 治療領域別

  • 概要
    • 治療領域別セグメントシェア分析
    • 神経学的障害
    • 感覚障害
    • 筋骨格障害
    • 代謝障害
    • 腫瘍性疾患
    • 希少疾患
    • 血液疾患
    • 免疫疾患
    • その他（生殖保健など）

第12章 ウイルスベクターおよびプラスミドDNA製造市場-地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • アジア太平洋地域の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東およびアフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第13章 主要ベンダー分析- ウイルスベクターおよびプラスミドDNA製造業界

  • 競合ダッシュボード
  • 企業プロファイル
    • CEVEC Pharmaceuticals
    • Catalent Biologics
    • Cobra Biologics
    • Altruist Biotechnology
    • NorthX Biologics
    • Novartis
    • BioReliance（a subsidiary of Merck KGaA）
    • Centre for Process Innovation
    • Wuxi AppTech
    • Charles River Laboratories
    • CoJourney
    • Esco Aster
    • Jiangsu Puxin Biopharmaceutical
    • Lonza
    • Advanced BioScience Laboratories
    • AGC Biologics
    • Aldevron
    • Biovian
    • Celonic
    • BioNTech Innovative Manufacturing Service（a subsidiary of BioNTech）
    • Oxford BioMedica
    • Sanofi
    • Thermo Fisher Scientific
    • VectorBuilder
    • Matica Biotechnology
    • Resilience
    • Nikon CeLL innovation

第14章 アナリストの全方位展望

図表

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Viral Vector and Plasmid DNA Manufacturing Market: Vector Type Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Vector Type
  • TABLE Global Viral Vector and Plasmid DNA Manufacturing Market, by Vector Type 2019-2032 (USD Million)
  • TABLE Viral Vector and Plasmid DNA Manufacturing Market: Workflow Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Workflow
  • TABLE Global Viral Vector and Plasmid DNA Manufacturing Market, by Workflow 2019-2032 (USD Million)
  • TABLE Viral Vector and Plasmid DNA Manufacturing Market: Application Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Application
  • TABLE Global Viral Vector and Plasmid DNA Manufacturing Market, by Application 2019-2032 (USD Million)
  • TABLE Viral Vector and Plasmid DNA Manufacturing Market: End-use Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by End-use
  • TABLE Global Viral Vector and Plasmid DNA Manufacturing Market, by End-use 2019-2032 (USD Million)
  • TABLE Viral Vector and Plasmid DNA Manufacturing Market: Therapeutic Area Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Therapeutic Area
  • TABLE Global Viral Vector and Plasmid DNA Manufacturing Market, by Therapeutic Area 2019-2032 (USD Million)
  • TABLE Viral Vector and Plasmid DNA Manufacturing Market: Regional snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Viral Vector and Plasmid DNA Manufacturing Market, by Region 2019-2032 (USD Million)
  • TABLE North America Viral Vector and Plasmid DNA Manufacturing Market, by Country, 2019-2032 (USD Million)
  • TABLE North America Viral Vector and Plasmid DNA Manufacturing Market, by Vector Type, 2019-2032 (USD Million)
  • TABLE North America Viral Vector and Plasmid DNA Manufacturing Market, by Workflow, 2019-2032 (USD Million)
  • TABLE North America Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2019-2032 (USD Million)
  • TABLE North America Viral Vector and Plasmid DNA Manufacturing Market, by End-use, 2019-2032 (USD Million)
  • TABLE North America Viral Vector and Plasmid DNA Manufacturing Market, by Therapeutic Area, 2019-2032 (USD Million)
  • TABLE Europe Viral Vector and Plasmid DNA Manufacturing Market, by Country, 2019-2032 (USD Million)
  • TABLE Europe Viral Vector and Plasmid DNA Manufacturing Market, by Vector Type, 2019-2032 (USD Million)
  • TABLE Europe Viral Vector and Plasmid DNA Manufacturing Market, by Workflow, 2019-2032 (USD Million)
  • TABLE Europe Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2019-2032 (USD Million)
  • TABLE Europe Viral Vector and Plasmid DNA Manufacturing Market, by End-use, 2019-2032 (USD Million)
  • TABLE Europe Viral Vector and Plasmid DNA Manufacturing Market, by Therapeutic Area, 2019-2032 (USD Million)
  • TABLE Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market, by Country, 2019-2032 (USD Million)
  • TABLE Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market, by Vector Type, 2019-2032 (USD Million)
  • TABLE Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market, by Workflow, 2019-2032 (USD Million)
  • TABLE Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2019-2032 (USD Million)
  • TABLE Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market, by End-use, 2019-2032 (USD Million)
  • TABLE Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market, by Therapeutic Area, 2019-2032 (USD Million)
  • TABLE Latin America Viral Vector and Plasmid DNA Manufacturing Market, by Country, 2019-2032 (USD Million)
  • TABLE Latin America Viral Vector and Plasmid DNA Manufacturing Market, by Vector Type, 2019-2032 (USD Million)
  • TABLE Latin America Viral Vector and Plasmid DNA Manufacturing Market, by Workflow, 2019-2032 (USD Million)
  • TABLE Latin America Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2019-2032 (USD Million)
  • TABLE Latin America Viral Vector and Plasmid DNA Manufacturing Market, by End-use, 2019-2032 (USD Million)
  • TABLE Latin America Viral Vector and Plasmid DNA Manufacturing Market, by Therapeutic Area, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Viral Vector and Plasmid DNA Manufacturing Market, by Country, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Viral Vector and Plasmid DNA Manufacturing Market, by Vector Type, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Viral Vector and Plasmid DNA Manufacturing Market, by Workflow, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Viral Vector and Plasmid DNA Manufacturing Market, by End-use, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Viral Vector and Plasmid DNA Manufacturing Market, by Therapeutic Area, 2019-2032 (USD Million)
目次
Product Code: ANV2473

REPORT HIGHLIGHT

Viral Vector and Plasmid DNA Manufacturing Market size was valued at USD 5,405 Million in 2023, expanding at a CAGR of 19.7% from 2024 to 2032.

Viral vectors and plasmid DNA can be employed in gene therapy to treat a wide range of diseases, such as cancer, metabolic issues, cardiac problems, and neurological disorders. As viral vectors are based on baculovirus, herpes simplex viruses, adenoviruses, and other viruses, they are being employed increasingly frequently in vaccine research and the development of novel medications.

Viral Vector and Plasmid DNA Manufacturing Market- Market Dynamics

Increasing government support for cell-based research to propel market demand

The market for Viral Vector and Plasmid DNA Manufacturing is expected to grow as a result of increased government funding for the creation of new technologies and facilities for producing viral vectors, which has increased overall research activity and supported cell-based research. In addition, the main drivers propelling market expansion are the growing prevalence of diseases including cancer and heart abnormalities, the use of cell therapies research, and technological advancements in the field of viral vector & plasmid DNA manufacture. For instance, the Canadian government made investments in genomics and regenerative medicine to promote the health of its citizens. Through the competitive research funding initiative of the Stem Cell Network, $4.3 million was awarded. 16 initiatives from around Canada that aim to treat health issues like multiple sclerosis, muscular dystrophy, cancer, blood diseases, diabetes type 1, heart disease, and cystic fibrosis will be supported by this direct funding. A new program to assist early career researchers in the health, bioengineering, and social sciences who are creating stem cell research initiatives with an emphasis on regenerative medicine was one of the funding opportunities featured in this competition. In addition, $16 million will be provided to ten new genomics studies through Genome Canada. By 2035, this investment will have contributed to the transformation of biomedicine and drug development. It will also support mission-driven research with direct application potential that tackles real-world problems and possibilities in the fields of agriculture, health, and the environment.

Rising product launches offer a potential opportunity for market revenue growth

The increasing product launch is expected to offer a potential opportunity for market growth during the forecast period. For instance, in March 2023, Adeno-associated virus (AAV)-based gene therapy initiatives can now be more efficiently managed from early discovery to commercial manufacture with the introduction of Charles River Laboratories International, Inc.'s off-the-shelf pHelper service. Research Grade (RG), High Quality (HQ), and Good Manufacturing Practice (GMP) grades are all instantly available.

Viral Vector and Plasmid DNA Manufacturing Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 19.7% over the forecast period (2024-2032)

Based on vector type segmentation, the Adeno-Associated Virus (AAV) segment is expected to hold the largest market share over the forecast period

Based on workflow segmentation, the Downstream Manufacturing segment is expected to hold a significant market share over the projected period

Based on the therapeutic area, the oncological disorder segment is expected to hold a prominent market share over the forecast period

Based on region, North America was the leading revenue generator in 2023

Viral Vector and Plasmid DNA Manufacturing Market- Segmentation Analysis:

The Global Viral Vector and Plasmid DNA Manufacturing Market is segmented based on Vector Type, Workflow, Application, End-use, Therapeutic Area, and Region.

Based on the vector type, the Viral Vector and Plasmid DNA Manufacturing market is segmented into Adenovirus, Lentivirus, Adeno-Associated Virus (AAV), Retrovirus, Plasmids, Baculovirus, Sendai Virus and Others (Herpes Simplex Virus (HSV), etc.). The Adeno-Associated Virus (AAV) segment is expected to hold the largest market share over the forecast period. Due to their exceptional precision in delivering the gene to the desired location, AAVs are extremely sought after and are being used in clinical trials at a rapid pace. Clinical investigations about the development of orthopedic and ophthalmic gene therapy medicines are showing enhanced efficacy and efficiency, which is the reason for the increasing adoption.

Based on the workflow, the Viral Vector and Plasmid DNA Manufacturing industry is bifurcated into Upstream Manufacturing and Downstream Manufacturing. The Downstream Manufacturing segment is expected to hold a significant market share over the projected period due to the extremely intricate processes used to polish and purify final products of therapeutic grade.

Based on the application, the market is bifurcated into Antisense & RNAi Therapy, Vaccinology, Gene Therapy, Tissue Engineering, Cell Therapy, Research Applications and Others (Biosensors, etc.).

Based on the end-use, the industry is bifurcated into Pharmaceutical and Biopharmaceutical Companies, Contract Manufacturing Organizations (CMOs, Research Institutes and Others (Government Agencies, etc.).

Based on the therapeutic area, the Viral Vector and Plasmid DNA Manufacturing market is bifurcated into Neurological Disorders, Sensory Disorders, Musculoskeletal Disorders, Metabolic Disorders, Oncological Disorders, Rare Diseases, Blood Disorders, Immunological Disorders and Others (Reproductive Health, etc.). The oncological disorder segment is expected to hold a prominent market share over the forecast period. The segment growth is attributed to the rising prevalence of cancer across the globe. For instance, according to the latest estimates by the International Agency for Research on Cancer (IARC), 20 million new instances of cancer and 9.7 million deaths from the disease are anticipated for 2022. 53.5 million people were predicted to still be alive five years after receiving a cancer diagnosis. One in five people will have cancer at some point in their lives; one in nine men and one in twelve women will pass away from the disease. Thus, the aforementioned statistics propel the segment expansion.

Viral Vector and Plasmid DNA Manufacturing Market- Geographical Insights

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to hold the largest market share over the forecast period. This is explained by the increasing number of contract development organizations in the area as well as the increasing involvement of businesses in gene and cell therapy research and product development. Furthermore, regional companies are growing their production plants in the area. Due to the existence of significant market participants, such as CDMOs providing GMP manufacturing services, and the use of highly creative manufacturing methods for production, the United States held the largest revenue share in the North American market for viral vectors and plasmid DNA manufacturing.

Viral Vector and Plasmid DNA Manufacturing Market- Competitive Landscape:

Several major businesses are implementing some strategic efforts to improve their market position and provide a wide range of services to customers. To boost market presence and revenue and obtain a competitive edge, organizations frequently engage in partnerships and agreements, joint ventures, expansion, service launches, product innovation and other tactics that fuel market growth. Recent years have seen a notable level of innovation in the market for plasmid DNA and viral vectors. Producers of plasmid DNA and viral vectors are continuously looking for new and effective solutions to meet the growing demand for enhanced gene therapy and vaccine development. The use of transient transfection technology for the large-scale manufacturing of viral vectors is one of the major developments in this market. Utilizing suspension cell culture techniques to produce viral vectors is another innovative approach. Big biotech and pharmaceutical corporations are buying up smaller vector and plasmid DNA producers more frequently to gain access to their patented technologies, knowledge, and manufacturing capabilities. As a result, there is market consolidation, which increases the power of established players over pricing and market share. By utilizing the infrastructure and resources of larger acquirers, smaller businesses can expand their operations and reach new markets. For instance, in February 2022, Exelead was purchased by Merck KGaA for around USD 780 million. Providing end users with full end-to-end CDMO services along the mRNA value chain would further improve Merck's Life Science offering.

Recent Developments:

In October 2023, AGC Biologics announced the expansion of their German pDNA manufacturing facility. It is anticipated that this will assist the business in shortening the manufacturing lead time.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

CEVEC Pharmaceuticals

Catalent Biologics

Cobra Biologics

Altruist Biotechnology

NorthX Biologics

Novartis

BioReliance (a subsidiary of Merck KGaA)

Centre for Process Innovation

Wuxi AppTech

Charles River Laboratories

CoJourney

Esco Aster

Jiangsu Puxin Biopharmaceutical

Lonza

Advanced BioScience Laboratories

AGC Biologics

Aldevron

Biovian

Celonic

BioNTech Innovative Manufacturing Service (a subsidiary of BioNTech)

Oxford BioMedica

Sanofi

Thermo Fisher Scientific

VectorBuilder

Matica Biotechnology

Resilience

Nikon CeLL innovation

GLOBAL VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE- MARKET ANALYSIS, 2019 - 2032

  • Adenovirus
  • Lentivirus
  • Adeno-Associated Virus (AAV)
  • Retrovirus
  • Plasmids
  • Baculovirus
  • Sendai Virus
  • Others (Herpes Simplex Virus (HSV), etc.)

GLOBAL VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW- MARKET ANALYSIS, 2019 - 2032

  • Upstream Manufacturing
  • Vector Amplification & Expansion
  • Vector Recovery/Harvesting
  • Downstream Manufacturing
  • Purification
  • Fill Finish

GLOBAL VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • Antisense & RNAi Therapy
  • Vaccinology
  • Gene Therapy
  • Tissue Engineering
  • Cell Therapy
  • Research Applications
  • Others (Biosensors, etc.)

GLOBAL VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END-USE- MARKET ANALYSIS, 2019 - 2032

  • Pharmaceutical and Biopharmaceutical Companies
  • Contract Manufacturing Organizations (CMOs)
  • Research Institutes
  • Others (Government Agencies, etc.)

GLOBAL VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY THERAPEUTIC AREA- MARKET ANALYSIS, 2019 - 2032

  • Neurological Disorders
  • Sensory Disorders
  • Musculoskeletal Disorders
  • Metabolic Disorders
  • Oncological Disorders
  • Rare Diseases
  • Blood Disorders
  • Immunological Disorders
  • Others (Reproductive Health, etc.)

GLOBAL VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Viral Vector and Plasmid DNA Manufacturing Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Viral Vector and Plasmid DNA Manufacturing Market Snippet by Vector Type
    • 2.1.2. Viral Vector and Plasmid DNA Manufacturing Market Snippet by Workflow
    • 2.1.3. Viral Vector and Plasmid DNA Manufacturing Market Snippet by Application
    • 2.1.4. Viral Vector and Plasmid DNA Manufacturing Market Snippet by End-use
    • 2.1.5. Viral Vector and Plasmid DNA Manufacturing Market Snippet by Therapeutic Area
    • 2.1.6. Viral Vector and Plasmid DNA Manufacturing Market Snippet by Country
    • 2.1.7. Viral Vector and Plasmid DNA Manufacturing Market Snippet by Region
  • 2.2. Competitive Insights

3. Viral Vector and Plasmid DNA Manufacturing Key Market Trends

  • 3.1. Viral Vector and Plasmid DNA Manufacturing Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Viral Vector and Plasmid DNA Manufacturing Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Viral Vector and Plasmid DNA Manufacturing Market Opportunities
  • 3.4. Viral Vector and Plasmid DNA Manufacturing Market Future Trends

4. Viral Vector and Plasmid DNA Manufacturing Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Viral Vector and Plasmid DNA Manufacturing Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Viral Vector and Plasmid DNA Manufacturing Market Landscape

  • 6.1. Viral Vector and Plasmid DNA Manufacturing Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Viral Vector and Plasmid DNA Manufacturing Market - By Vector Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Vector Type, 2023 & 2032 (%)
    • 7.1.2. Adenovirus
    • 7.1.3. Lentivirus
    • 7.1.4. Adeno-Associated Virus (AAV)
    • 7.1.5. Retrovirus
    • 7.1.6. Plasmids
    • 7.1.7. Baculovirus
    • 7.1.8. Sendai Virus
    • 7.1.9. Others (Herpes Simplex Virus (HSV), etc.)

8. Viral Vector and Plasmid DNA Manufacturing Market - By Workflow

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Workflow, 2023 & 2032 (%)
    • 8.1.2. Upstream Manufacturing
      • 8.1.2.1. Vector Amplification & Expansion
      • 8.1.2.2. Vector Recovery/Harvesting
    • 8.1.3. Downstream Manufacturing
      • 8.1.3.1. Purification
      • 8.1.3.2. Fill Finish

9. Viral Vector and Plasmid DNA Manufacturing Market - By Application

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Application, 2023 & 2032 (%)
    • 9.1.2. Antisense & RNAi Therapy
    • 9.1.3. Vaccinology
    • 9.1.4. Gene Therapy
    • 9.1.5. Tissue Engineering
    • 9.1.6. Cell Therapy
    • 9.1.7. Research Applications
    • 9.1.8. Others (Biosensors, etc.)

10. Viral Vector and Plasmid DNA Manufacturing Market - By End-use

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End-use, 2023 & 2032 (%)
    • 10.1.2. Pharmaceutical and Biopharmaceutical Companies
    • 10.1.3. Contract Manufacturing Organizations (CMOs)
    • 10.1.4. Research Institutes
    • 10.1.5. Others (Government Agencies, etc.)

11. Viral Vector and Plasmid DNA Manufacturing Market - By Therapeutic Area

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By Therapeutic Area, 2023 & 2032 (%)
    • 11.1.2. Neurological Disorders
    • 11.1.3. Sensory Disorders
    • 11.1.4. Musculoskeletal Disorders
    • 11.1.5. Metabolic Disorders
    • 11.1.6. Oncological Disorders
    • 11.1.7. Rare Diseases
    • 11.1.8. Blood Disorders
    • 11.1.9. Immunological Disorders
    • 11.1.10. Others (Reproductive Health, etc.)

12. Viral Vector and Plasmid DNA Manufacturing Market- By Geography

  • 12.1. Introduction
    • 12.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 12.2. North America
    • 12.2.1. Overview
    • 12.2.2. Viral Vector and Plasmid DNA Manufacturing Key Manufacturers in North America
    • 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.2.4. North America Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 12.2.5. North America Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
    • 12.2.6. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.2.7. North America Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
    • 12.2.8. North America Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.2.9. U.S.
      • 12.2.9.1. Overview
      • 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.9.3. U.S. Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.2.9.4. U.S. Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.2.9.5. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.2.9.6. U.S. Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.2.9.7. U.S. Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.2.10. Canada
      • 12.2.10.1. Overview
      • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.10.3. Canada Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.2.10.4. Canada Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.2.10.5. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.2.10.6. Canada Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.2.10.7. Canada Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  • 12.3. Europe
    • 12.3.1. Overview
    • 12.3.2. Viral Vector and Plasmid DNA Manufacturing Key Manufacturers in Europe
    • 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.3.4. Europe Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 12.3.5. Europe Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
    • 12.3.6. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.7. Europe Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
    • 12.3.8. Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.3.9. Germany
      • 12.3.9.1. Overview
      • 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.9.3. Germany Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.3.9.4. Germany Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.3.9.5. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.9.6. Germany Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.3.9.7. Germany Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.3.10. Italy
      • 12.3.10.1. Overview
      • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.10.3. Italy Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.3.10.4. Italy Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.3.10.5. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.10.6. Italy Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.3.10.7. Italy Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.3.11. United Kingdom
      • 12.3.11.1. Overview
      • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.11.3. United Kingdom Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.3.11.4. United Kingdom Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.3.11.5. United Kingdom Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.11.6. United Kingdom Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.3.11.7. United Kingdom Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.3.12. France
      • 12.3.12.1. Overview
      • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.12.3. France Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.3.12.4. France Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.3.12.5. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.12.6. France Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.3.12.7. France Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.3.13. Russia
      • 12.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.13.2. Russia Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.3.13.3. Russia Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.3.13.4. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.13.5. Russia Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.3.13.6. Russia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.3.14. Netherlands
      • 12.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.14.2. Netherlands Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.3.14.3. Netherlands Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.3.14.4. Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.14.5. Netherlands Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.3.14.6. Netherlands Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.3.15. Sweden
      • 12.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.15.2. Sweden Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.3.15.3. Sweden Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.3.15.4. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.15.5. Sweden Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.3.15.6. Sweden Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.3.16. Poland
      • 12.3.16.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.16.2. Poland Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.3.16.3. Poland Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.3.16.4. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.16.5. Poland Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.3.16.6. Poland Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.3.17. Rest of Europe
      • 12.3.17.1. Overview
      • 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.17.3. Rest of the Europe Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.3.17.4. Rest of the Europe Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.3.17.5. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.17.6. Rest of the Europe Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.3.17.7. Rest of the Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  • 12.4. Asia Pacific (APAC)
    • 12.4.1. Overview
    • 12.4.2. Viral Vector and Plasmid DNA Manufacturing Key Manufacturers in Asia Pacific
    • 12.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.4.4. Asia Pacific Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 12.4.5. Asia Pacific Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
    • 12.4.6. Asia Pacific Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.7. Asia Pacific Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
    • 12.4.8. Asia Pacific Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.4.9. India
      • 12.4.9.1. Overview
      • 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.9.3. India Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.4.9.4. India Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.4.9.5. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.9.6. India Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.4.9.7. India Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.4.10. China
      • 12.4.10.1. Overview
      • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.10.3. China Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.4.10.4. China Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.4.10.5. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.10.6. China Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.4.10.7. China Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.4.11. Japan
      • 12.4.11.1. Overview
      • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.11.3. Japan Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.4.11.4. Japan Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.4.11.5. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.11.6. Japan Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.4.11.7. Japan Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.4.12. South Korea
      • 12.4.12.1. Overview
      • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.12.3. South Korea Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.4.12.4. South Korea Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.4.12.5. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.12.6. South Korea Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.4.12.7. South Korea Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.4.13. Australia
      • 12.4.13.1. Overview
      • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.13.3. Australia Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.4.13.4. Australia Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.4.13.5. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.13.6. Australia Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.4.13.7. Australia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.4.14. Thailand
      • 12.4.14.1. Overview
      • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.14.3. Thailand Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.4.14.4. Thailand Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.4.14.5. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.14.6. Thailand Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.4.14.7. Thailand Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.4.15. Indonesia
      • 12.4.15.1. Overview
      • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.15.3. Indonesia Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.4.15.4. Indonesia Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.4.15.5. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.15.6. Indonesia Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.4.15.7. Indonesia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.4.16. Philippines
      • 12.4.16.1. Overview
      • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.16.3. Philippines Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.4.16.4. Philippines Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.4.16.5. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.16.6. Philippines Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.4.16.7. Philippines Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.4.17. Rest of APAC
      • 12.4.17.1. Overview
      • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.17.3. Rest of APAC Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.4.17.4. Rest of APAC Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.4.17.5. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.17.6. Rest of APAC Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.4.17.7. Rest of APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  • 12.5. Latin America
    • 12.5.1. Overview
    • 12.5.2. Viral Vector and Plasmid DNA Manufacturing Key Manufacturers in Latin America
    • 12.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.5.4. Latin America Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 12.5.5. Latin America Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
    • 12.5.6. Latin America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.5.7. Latin America Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
    • 12.5.8. Latin America Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.5.9. Brazil
      • 12.5.9.1. Overview
      • 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.9.3. Brazil Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.5.9.4. Brazil Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.5.9.5. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.9.6. Brazil Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.5.9.7. Brazil Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.5.10. Mexico
      • 12.5.10.1. Overview
      • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.10.3. Mexico Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.5.10.4. Mexico Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.5.10.5. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.10.6. Mexico Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.5.10.7. Mexico Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.5.11. Argentina
      • 12.5.11.1. Overview
      • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.11.3. Argentina Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.5.11.4. Argentina Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.5.11.5. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.11.6. Argentina Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.5.11.7. Argentina Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.5.12. Colombia
      • 12.5.12.1. Overview
      • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.12.3. Colombia Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.5.12.4. Colombia Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.5.12.5. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.12.6. Colombia Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.5.12.7. Colombia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.5.13. Rest of LATAM
      • 12.5.13.1. Overview
      • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.13.3. Rest of LATAM Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.5.13.4. Rest of LATAM Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.5.13.5. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.13.6. Rest of LATAM Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.5.13.7. Rest of LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  • 12.6. Middle East and Africa
    • 12.6.1. Overview
    • 12.6.2. Viral Vector and Plasmid DNA Manufacturing Key Manufacturers in Middle East and Africa
    • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.6.4. Middle East and Africa Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 12.6.5. Middle East and Africa Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
    • 12.6.6. Middle East and Africa Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.7. Middle East and Africa Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
    • 12.6.8. Middle East and Africa Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.6.9. Saudi Arabia
      • 12.6.9.1. Overview
      • 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.9.3. Saudi Arabia Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.6.9.4. Saudi Arabia Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.6.9.5. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.9.6. Saudi Arabia Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.6.9.7. Saudi Arabia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.6.10. United Arab Emirates
      • 12.6.10.1. Overview
      • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.10.3. United Arab Emirates Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.6.10.4. United Arab Emirates Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.6.10.5. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.10.6. United Arab Emirates Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.6.10.7. United Arab Emirates Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.6.11. Israel
      • 12.6.11.1. Overview
      • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.11.3. Israel Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.6.11.4. Israel Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.6.11.5. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.11.6. Israel Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.6.11.7. Israel Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.6.12. Turkey
      • 12.6.12.1. Overview
      • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.12.3. Turkey Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.6.12.4. Turkey Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.6.12.5. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.12.6. Turkey Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.6.12.7. Turkey Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.6.13. Algeria
      • 12.6.13.1. Overview
      • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.13.3. Algeria Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.6.13.4. Algeria Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.6.13.5. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.13.6. Algeria Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.6.13.7. Algeria Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.6.14. Egypt
      • 12.6.14.1. Overview
      • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.14.3. Egypt Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.6.14.4. Egypt Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.6.14.5. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.14.6. Egypt Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.6.14.7. Egypt Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.6.15. Rest of MEA
      • 12.6.15.1. Overview
      • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.15.3. Rest of MEA Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.6.15.4. Rest of MEA Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.6.15.5. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.15.6. Rest of MEA Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.6.15.7. Rest of MEA Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Viral Vector and Plasmid DNA Manufacturing Industry

  • 13.1. Competitive Dashboard
  • 13.2. Company Profiles
    • 13.2.1. CEVEC Pharmaceuticals
    • 13.2.2. Catalent Biologics
    • 13.2.3. Cobra Biologics
    • 13.2.4. Altruist Biotechnology
    • 13.2.5. NorthX Biologics
    • 13.2.6. Novartis
    • 13.2.7. BioReliance (a subsidiary of Merck KGaA)
    • 13.2.8. Centre for Process Innovation
    • 13.2.9. Wuxi AppTech
    • 13.2.10. Charles River Laboratories
    • 13.2.11. CoJourney
    • 13.2.12. Esco Aster
    • 13.2.13. Jiangsu Puxin Biopharmaceutical
    • 13.2.14. Lonza
    • 13.2.15. Advanced BioScience Laboratories
    • 13.2.16. AGC Biologics
    • 13.2.17. Aldevron
    • 13.2.18. Biovian
    • 13.2.19. Celonic
    • 13.2.20. BioNTech Innovative Manufacturing Service (a subsidiary of BioNTech)
    • 13.2.21. Oxford BioMedica
    • 13.2.22. Sanofi
    • 13.2.23. Thermo Fisher Scientific
    • 13.2.24. VectorBuilder
    • 13.2.25. Matica Biotechnology
    • 13.2.26. Resilience
    • 13.2.27. Nikon CeLL innovation

14. 360 Degree Analyst View

15. Appendix

  • 15.1. Research Methodology
  • 15.2. References
  • 15.3. Abbreviations
  • 15.4. Disclaimer
  • 15.5. Contact Us